• A Direct Visual Cortex–Entorhinal Pathway in Spatial Navigat

  2026-05-05

  This study uncovers a previously uncharacterized pathway from the secondary visual cortex to layer 5a of the medial entorhinal cortex (MEC), demonstrating its key role in transmitting visual information for spatial navigation. The findings reshape our understanding of sensory integration in the entorhinal-hippocampal network and inform future circuit dissection strategies.

• Lysoptosis: Evolutionary Cell Death Moderated by Intracellul

  2026-05-04

  The reference study uncovers lysoptosis as an evolutionarily conserved, lysosome-dependent cell death pathway, distinct from apoptosis and necrosis, and governed by intracellular serpins. This work clarifies the mechanistic role of lysosomal membrane permeabilization and cathepsin release in regulated cell death, informing the strategic use of cysteine protease inhibitors like E-64d in dissecting cell death mechanisms.

• Applied Protocols with Recombinant Human EGF: Maximizing Cel

  2026-05-04

  Recombinant human EGF, expressed in E. coli and supplied by APExBIO, drives consistent results in cell migration, proliferation, and mucosal healing assays. This guide delivers actionable workflows, troubleshooting insights, and advanced use-case translation based on both product data and new findings on EGF-driven cellular migration.

• Practical Use of Oligo (dT) 25 Beads for Eukaryotic mRNA Iso

  2026-05-03

  Oligo (dT) 25 Beads provide a robust solution for rapid, high-purity isolation of eukaryotic mRNA from total RNA or lysates, streamlining workflows for downstream molecular biology applications. They are best suited for protocols requiring polyA tail mRNA capture, especially when sample integrity and reproducibility are critical. Not recommended for prokaryotic RNA or applications requiring non-polyadenylated RNA enrichment.

• Fludarabine as a Precision Tool for Genomic Oncology Models

  2026-05-02

  Explore how Fludarabine, a leading DNA synthesis inhibitor, enables precision studies in leukemia and multiple myeloma research. This article offers a unique perspective on integrating genomic profiling insights with advanced apoptosis and cell cycle assays.

• Dabigatran Etexilate: Clinical Impact as an Oral Thrombin In

  2026-05-01

  This article reviews the pivotal innovation and clinical findings of Dabigatran etexilate as the first oral direct thrombin inhibitor, based on a comprehensive clinical review. The reference study highlights Dabigatran's rapid, predictable anticoagulant effects and its transformative role in venous thromboembolism and stroke prevention, offering an alternative to traditional anticoagulants with fewer monitoring requirements and oral administration.

• Merbromin as a Selective Mixed-Type Inhibitor of SARS-CoV-2

  2026-05-01

  This study identifies Merbromin as a potent, selective mixed-type inhibitor of the SARS-CoV-2 main protease 3CLpro using high-throughput screening and enzyme kinetics. The research delineates Merbromin’s mechanism, offering a foundation for the rational design of new antiviral agents targeting coronavirus replication.

• TCAIM-Mediated OGDH Proteolysis: A New Layer in Mitochondria

  2026-04-30

  The reference study uncovers TCAIM, a novel mitochondrial DNAJ protein, as a specific regulator of α-ketoglutarate dehydrogenase (OGDH) proteolysis and mitochondrial metabolism. By elucidating the TCAIM–OGDH interaction and its impact on bioenergetics, the work adds mechanistic insight into mitochondrial proteostasis with implications for metabolic research.

• Dabigatran Etexilate: Direct Thrombin Inhibitor for Coagulat

  2026-04-30

  Dabigatran etexilate is a potent oral direct thrombin inhibitor used in anticoagulant research for atrial fibrillation and stroke prevention. Its defined mechanism, predictable pharmacology, and robust in vitro and in vivo efficacy make it a benchmark compound for studying the coagulation cascade and developing translational therapies.

• Dabigatran Etexilate: Direct Thrombin Inhibitor in Research

  2026-04-29

  Dabigatran etexilate stands out as a potent, selective oral direct thrombin inhibitor, offering predictable anticoagulant effects for bench research on coagulation and atrial fibrillation. Explore optimal protocols, troubleshooting strategies, and advanced use-cases that leverage its unique pharmacological profile and high purity from APExBIO.

• Dabigatran Etexilate: Defining Selectivity in Thrombin Resea

  2026-04-29

  Explore Dabigatran etexilate, a direct thrombin inhibitor, with a rigorous analysis of its selectivity, mechanisms, and pivotal role in advanced anticoagulant research. Uncover evidence-based guidance for protocol design and practical application in atrial fibrillation and stroke prevention studies.

• Ceftazidime: Third-Generation Cephalosporin for Gram-Negativ

  2026-04-28

  Ceftazidime is a third-generation cephalosporin antibiotic with proven efficacy against Gram-negative pathogens, especially Pseudomonas aeruginosa. Its β-lactamase resistance and broad-spectrum profile make it essential for both clinical treatment and infection research. Recent data underscore its utility and boundaries, particularly amid rising multidrug resistance.

• Chloramphenicol in Plasmid Selection: Protocols & Innovation

  2026-04-28

  Chloramphenicol, a potent bacterial protein synthesis inhibitor, underpins high-stringency plasmid selection and resistance gene studies. This guide translates new findings and APExBIO’s rigorous standards into practical workflows, troubleshooting strategies, and actionable optimizations for molecular biology researchers.

• Dabigatran in Translational Research: Mechanism to Practice

  2026-04-27

  This thought-leadership article offers translational researchers a deep mechanistic understanding of Dabigatran (Pradaxa) as a reversible direct thrombin inhibitor, synthesizing leading-edge insights with strategic guidance for experimental design, assay selection, and clinical translation. By integrating evidence from clinical pharmacology, comparative metabolomic studies, and recent research advances, the article frames Dabigatran’s unique attributes within the evolving anticoagulation landscape, while contextually highlighting APExBIO’s contribution to the field.

• Buffer Optimization Stabilizes RNA-LNPs During Nebulization

  2026-04-27

  This study presents a systematic approach to stabilize RNA-loaded lipid nanoparticles (LNPs) during nebulization by selecting appropriate buffer excipients. The findings demonstrate that buffer composition critically influences nanoparticle integrity, RNA retention, and bioactivity, offering a generalizable strategy for effective pulmonary RNA delivery.

16764 records 1/1118 page Next 12345 下5页 Last page